Enhancing the Immunogenicity of a Tetravalent Dengue DNA Vaccine

Abstract

Dengue fever ranks among the top infectious diseases that afflict US Military personnel deployed overseas. Developing a successful vaccine to prevent dengue fever in DoD personnel is priority research area for the US DoD. Phase 1 clinical trials demonstrated that the Naval Medical Research Centers DNA based dengue vaccine is safe and well tolerated, but does not elicit a sufficient immune response. The objectives of this project are to conduct studies in non-human primates to enhance the immunogenicity of the vaccine by (a) testing different modes of delivery of dengue DNA vaccine for optimal humoral and T cell responses, and (b) testing the optimal delivery method in conjunction with other vaccine platforms using a heterologous prime-boost regimen. All necessary contracts are in place, the vaccine product is ready and the first vaccinations to address objective (a) are scheduled for early October 2016.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2016
Accession Number
AD1020595

Entities

People

  • Maya Williams

Organizations

  • Henry M. Jackson Foundation for the Advancement of Military Medicine

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Blood
  • Cells
  • Clinical Trials
  • Contracts
  • Dengue
  • Department Of Defense
  • Diseases And Disorders
  • Immunization
  • Immunogenicity
  • Infectious Diseases
  • Lymphocytes
  • Medical Personnel
  • Military Personnel
  • Vaccination
  • Vaccines
  • Virus Diseases

Readers

  • Defense Acquisition Program Management
  • Immunology
  • Infectious Disease/Epidemiology

Technology Areas

  • Biotechnology